HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Petra Baumgaertner Selected Research

MART-1 Antigen

1/2019Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma.
11/2012Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
6/2012Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose.
6/2012Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.
12/2011Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.
6/2011Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
10/2010Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
8/2010Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma.
10/2009Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.
3/2007IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Petra Baumgaertner Research Topics

Disease

34Neoplasms (Cancer)
01/2022 - 09/2006
30Melanoma (Melanoma, Malignant)
01/2021 - 02/2006
4Neoplasm Metastasis (Metastasis)
05/2015 - 06/2011
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 07/2019
2Human Influenza (Influenza)
12/2011 - 08/2010
2Testicular Neoplasms (Testicular Cancer)
09/2008 - 02/2006
1Endometrial Neoplasms (Endometrial Cancer)
11/2021
1Adenocarcinoma
11/2021
1Lung Neoplasms (Lung Cancer)
01/2021
1Colorectal Neoplasms (Colorectal Cancer)
11/2017
1Virus Diseases (Viral Diseases)
01/2010

Drug/Important Bio-Agent (IBA)

20Peptides (Polypeptides)IBA
11/2021 - 02/2006
13AntigensIBA
01/2022 - 02/2006
12MART-1 AntigenIBA
01/2019 - 07/2006
8VaccinesIBA
11/2021 - 01/2010
5Neoplasm Antigens (Tumor Antigens)IBA
01/2022 - 02/2006
4CytokinesIBA
01/2021 - 06/2012
4LigandsIBA
05/2015 - 10/2010
3Proteins (Proteins, Gene)FDA Link
01/2021 - 03/2007
3incomplete Freund's adjuvantIBA
03/2016 - 02/2006
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2022 - 09/2008
2Biomarkers (Surrogate Marker)IBA
01/2021 - 01/2019
2HLA Antigens (Human Leukocyte Antigens)IBA
01/2019 - 10/2009
2Monatide (IMS 3015)IBA
03/2016 - 11/2012
2IpilimumabIBA
05/2015 - 03/2014
2Biotin (Vitamin H)FDA Link
12/2011 - 09/2006
2HLA-A2 Antigen (HLA A2 Antigen)IBA
10/2010 - 09/2006
2HLA-A*02:01 antigenIBA
08/2010 - 09/2008
2AutoantigensIBA
10/2009 - 03/2008
1PlatinumIBA
11/2021
1Immune Checkpoint InhibitorsIBA
01/2021
1Interleukin-6 (Interleukin 6)IBA
01/2021
1EpitopesIBA
01/2021
1Hypochlorous Acid (Hypochlorite)IBA
06/2020
1ProteomeIBA
06/2020
1NivolumabIBA
07/2019
1pembrolizumabIBA
07/2019
1Biological ProductsIBA
01/2019
1Tetanus Toxoid (Vaccine, Tetanus)FDA Link
01/2019
1Messenger RNA (mRNA)IBA
11/2017
1RNA (Ribonucleic Acid)IBA
11/2017
1Freund's AdjuvantIBA
01/2017
1Toll-Like Receptor AgonistsIBA
03/2016
1human soluble LAG-3 proteinIBA
03/2016
1Integrin alpha1beta1IBA
01/2016
1peptide PIBA
07/2015
1Monoclonal AntibodiesIBA
05/2015
1Cancer VaccinesIBA
12/2014
1AntibodiesIBA
12/2014
1HLA-DR Antigens (HLA-DR)IBA
03/2014
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
03/2014
1OligonucleotidesIBA
11/2012
1CPG-oligonucleotideIBA
11/2012
1ProMune (CpG 7909)IBA
06/2012
1Blocking AntibodiesIBA
01/2012
1nickel nitrilotriacetic acidIBA
12/2011
1Toll-Like Receptor 9IBA
10/2010
1Interleukin-2 (IL2)IBA
10/2010
1Indicators and Reagents (Reagents)IBA
08/2010
1Coloring Agents (Dyes)IBA
08/2010
1Membrane Proteins (Integral Membrane Proteins)IBA
10/2009
1OligodeoxyribonucleotidesIBA
03/2008
1Vaccine AdjuvantsIBA
03/2008
1Granzymes (Granzyme)IBA
03/2007
1PerforinIBA
03/2007
1EmulsionsIBA
02/2006
1Differentiation AntigensIBA
02/2006

Therapy/Procedure

9Therapeutics
01/2021 - 06/2011
7Immunotherapy
11/2021 - 10/2009
2Drug Therapy (Chemotherapy)
11/2021 - 03/2014
2Cell- and Tissue-Based Therapy (Cell Therapy)
12/2020 - 05/2015
1Radiotherapy
01/2021
1Injections
01/2019